Sign in

    Eason Lee • Leerink Partners

    Eason Lee is an Equity Research Analyst at Leerink Partners, specializing in diversified biopharmaceuticals and targeted oncology, with direct coverage of companies including Abbisko Therapeutics, Agios Pharmaceuticals, Arvinas, Xencor, and Zai Lab. Since joining Leerink Partners as an Associate in 2017, Lee advanced through roles at the firm and completed a tenure as a Research Associate at Needham & Co. from 2022 to 2024 before returning to Leerink as a lead analyst in 2024. Lee holds both undergraduate and graduate degrees from Duke University, earned in 2012 and 2014, respectively, and maintains FINRA Series 7 and 63 licenses. He has built a reputation for detailed financial modeling and sector expertise in biopharma, delivering stock ratings and forecasts for a portfolio of high-profile public biotech companies.

    Eason Lee's questions to Celcuity Inc (CELC) leadership

    Eason Lee's questions to Celcuity Inc (CELC) leadership • Q2 2025

    Question

    Eason Lee of Leerink Partners questioned the use of Blinded Independent Central Review (BICR) for the PFS endpoint, asking if investigator-assessed data would also be presented and about the typical concordance between the two methods as viewed by regulators.

    Answer

    CEO Brian Sullivan clarified that BICR is the FDA-recommended method for open-label studies like VICTORIA-1 to eliminate potential investigator bias. He noted that investigator-assessed data is exploratory and will be presented later. He expressed high confidence in the data, citing studies showing high concordance (over 95%) between BICR and investigator assessments and confirming that sensitivity analyses prescribed by the FDA show the data is robust.

    Ask Fintool Equity Research AI